Search results
Results from the WOW.Com Content Network
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2] It is developed by Intra-Cellular Therapies, licensed from Bristol ...
Bipolar disorder can also involve depressive episodes, which have the same symptoms that people with major depressive disorder experience. Symptoms of a depressive episode can include : Feeling ...
Cariprazine is used to treat patients with schizophrenia and manic, depressive, or mixed episodes associated with bipolar I disorder.In the United States it is approved for schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and treatment of depressive episodes associated with bipolar I disorder (bipolar depression).
The drug seems ineffective in the treatment of current rapid-cycling, acute mania, or acute depression in bipolar disorder. [26] Lamotrigine has been shown to be as effective as lithium, the standard treatment for bipolar disorder. [27] Lamotrigine has not demonstrated clear efficacy in treating acute mood episodes, either mania or depression.
At least five atypical antipsychotics (lumateperone, [48] cariprazine, [49] lurasidone, [50] olanzapine, [51] and quetiapine [52]) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine [53] and quetiapine [54] [55] have been proven to be effective broad-spectrum (i.e., against ...
Duloxetine is one of the most commonly used prescription medications in the U.S. Patients with depression are usually prescribed 40 to 60 milligrams per day, with a potential increase of up to 120 ...
Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder. [2] [3] [4] A regulatory application for approval of the medication is expected to be submitted by 2025. [2] Aticaprant is taken by mouth. [1]
Treatment of depression of all forms and severities (endogenous, psychotic, involutional, and neurotic), especially depression associated with agitation or anxiety; Panic disorder; Neuropathic pain, including painful polyneuropathy in diabetics and non-diabetics alike. [14] Treatment of the depressive phase of bipolar affective disorder